Roivant Sciences Ltd.

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies, known as "Vants". Founded in 2014 by Vivek Ramaswamy, its mission is to improve health by rapidly delivering innovative medicines and technologies to patients, specifically by treating diseases of high unmet medical need. The company's primary operational headquarters are located in New York City, NY, USA, with additional major offices in Boston and Basel.

Roivant operates a broad and differentiated pipeline of investigational drugs across numerous therapeutic areas, primarily focusing on immunology and specialty diseases. Key therapeutic areas include dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, lichen planopilaris, pulmonary hypertension associated with interstitial lung disease, and IgG-mediated autoimmune diseases. The company also has a commercial-stage product, VTAMA (tapinarof) cream, 1%, for the topical treatment of plaque psoriasis in adults, which was launched in 2022.

Under the leadership of CEO Matt Gline, Roivant has recently seen significant developments, including a $2.25 billion settlement with Moderna in March 2026 related to COVID-19 vaccine patents, substantially strengthening its financial position. The company is advancing its pipeline with positive Phase 3 trial results for brepocitinib in dermatomyositis published in March 2026, and an expanded development program for brepocitinib into lichen planopilaris in April 2026. Roivant also completed a $1 billion share repurchase program in late 2025/early 2026 and was included in the S&P MidCap 400 as of April 1, 2024, reflecting its market positioning as a commercial-stage biopharmaceutical company aiming to be a "next-generation 'big pharma'".